Search results
Results from the WOW.Com Content Network
JCO Oncology Practice [1] (known from 2005 to 2019 as the Journal of Oncology Practice) [2] is a monthly peer-reviewed medical journal covering the mechanics of oncology care. It was established in 2005 and is published by the American Society of Clinical Oncology. The editor-in-chief is John V. Cox (UT Southwestern Medical Center). [3]
Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be classified as having “symptomatic deterioration”. Every effort should be made to document the objective progression even after discontinuation of treatment.
PFS is widely used as a surrogate endpoint in oncology. [4] The definition of "progression" generally involves imaging techniques (plain radiograms, CT scans, MRI, PET scans, ultrasounds) or other aspects: biochemical progression may be defined on the basis of an increase in a tumor marker (such as CA125 for epithelial ovarian cancer or PSA for prostate cancer).
The first edition, titled Clinical Oncology, was published by Churchill Livingstone in 1995. [1] In 2000, a second edition was released with an extra chapter on cancer prevention and screening. [2] A third edition was released four years later with more updates over the previous edition. [3] Its founding editor, Martin Abeloff, died in 2007. [4]
1900 – Swedish Dr. Stenbeck cures a skin cancer with small doses of radiation [4]; 1920s – Dr. William B. Coley's immunotherapy treatment, regressed tumors in hundreds of cases, the success of Coley's Toxins attracted heavy resistance from his rival and supervisor, Dr. James Ewing, who was an ardent supporter of radiation therapy for cancer.
The Journal of Clinical Oncology is a peer-reviewed medical journal published 3 times a month by the Lippincott Williams & Wilkins. It covers research on all aspects of clinical oncology. The journal was established in 1983 and the editor-in-chief is Jonathan W. Friedberg (University of Rochester). JCO's Impact Factor is 45.3 as reported by ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Database Institute / Organization Alteration Types Primary Source [t 1] Processed Data [t 2] Organisms Cell lines [t 3] Public Data [t 4] Restricted Data [t 5]; The BioExpress® Oncology Suite from Ocimum Bio Solutions contains gene expression data from primary, metastatic, and benign tumor samples, and normal samples, including matched adjacent controls.